Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer

By sjmartinez • December 30, 2025

Thaker SK, Silverstein J, Konecny GE, Bardia A. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2026 Feb 1;38(1):48-56. doi: 10.1097/GCO.0000000000001080. Epub 2025 Dec 22. PMID: 41461040.

Tags: antibody, directed therapy, drug conjugates, Fellow, Hematology/Oncology, human epidermal growth factor receptor 2, Publications, trastuzumab deruxtecan

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf[...]

Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report

Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026[...]

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]